Karachi: In its annual report to shareholders dated June 30, 2024, Searle Pakistan Limited highlighted a year of robust financial performance amidst challenging economic conditions, achieving a turnover of PKR 25.83 billion, a 19% increase from the previous year. This growth was primarily fueled by strategic cost management and a focus on expanding into high-margin products.

According to information available from the Pakistan Stock Exchange (PSX), Searle has navigated the pressures of soaring inflation and a depreciating rupee with resilience, particularly stressed by high costs for raw materials and active pharmaceutical ingredients. These challenges have significantly squeezed profit margins across Pakistan’s pharmaceutical industry.

The chairman’s report detailed several strategic moves by Searle, including the planned divestiture of its subsidiary, Searle Pakistan Limited (SPL), scheduled for May 2024. The decision is driven by a need to address liquidity challenges and refocus resources on more profitable opportunities, amidst rising interest rates and currency fluctuations affecting SPL’s performance. Discussions with IJARA Capital Partners Limited (ICPL) to finalize the sale are ongoing, pending regulatory approvals.

Reflecting on regulatory changes, Searle anticipates further financial flexibility from the deregulation of pricing for non-essential drugs, which could enhance profitability and cash flows. This is seen as a pivotal adjustment that could allow more rapid deployment of new products into the market.

The company remains committed to its mission of delivering high-quality healthcare solutions and is poised to continue its expansion both domestically and into international markets, focusing on specialty generic branded offerings and innovative product development.

Despite the divestiture and ongoing macroeconomic hurdles, Searle's dedication to operational excellence and strategic market positioning is expected to drive sustained growth and profitability.